SSKN

Strata Skin Sciences Inc

Add to Watchlist

Advanced Chart

1.640

+0.02(1.235%)1D

Line

Candle

YTD

High

1.666

Open

1.620

VWAP

1.59

Vol

132.54K

Mkt Cap

8.64M

Low

1.540

Amount

210.32K

EV/EBITDA(TTM)

Total Shares

3.51M

17.94M

EV/OCF(TTM)

P/S(TTM)

0.21

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

7.72M

-12.28%

-0.530

-0%

8.39M

-12.6%

-0.400

-66.1%

7.42M

+8.9%

-0.445

-23.28%

Estimates Revision

The market is revising No Change the revenue expectations for STRATA Skin Sciences, Inc. (SSKN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.87%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-7.87%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast SSKN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SSKN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.640

Low

4.00

Averages

4.00

High

4.00

Current: 1.640

Low

4.00

Averages

4.00

High

4.00

Maxim Group

Anthony Vendetti

Strong Buy

Initiates

2025-02-27

Reason

Maxim Group

Anthony Vendetti

Price Target

2025-02-27

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Strata Skin Sciences Inc (SSKN.O) is -1.02, compared to its 5-year average forward P/E of -6.84. For a more detailed relative valuation and DCF analysis to assess Strata Skin Sciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.84

Current PE

-1.02

Overvalued PE

-1.34

Undervalued PE

-12.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.55

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

34.47

Undervalued EV/EBITDA

-33.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.93

Current PS

1.64

Overvalued PS

1.50

Undervalued PS

0.36

Financials

Annual

Quarterly

FY2025Q2

YoY :

-9.15%

7.66M

Total Revenue

FY2025Q2

YoY :

+357.61%

-2.22M

Operating Profit

FY2025Q2

YoY :

+2414.14%

-2.49M

Net Income after Tax

FY2025Q2

YoY :

+1900.00%

-0.60

EPS - Diluted

FY2025Q2

YoY :

-889.02%

-1.94M

Free Cash Flow

FY2025Q2

YoY :

-4.00%

56.19

Gross Profit Margin - %

FY2025Q2

YoY :

+2676.07%

-32.48

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SSKN News & Events

Events Timeline

2025-10-28 (ET)

2025-10-28

08:18:26

Strata Skin Sciences Receives COFEPRIS Approval for TheraClear in Mexico

2025-10-20 (ET)

2025-10-20

08:21:34

Strata Skin Sciences Offers Update on Legal Matters and Strategic Positioning

2025-10-14 (ET)

2025-10-14

08:29:21

Strata Skin Sciences Reveals Clinical Case Study on 308-nm Excimer Laser

News

9.5

10-29Benzinga

Teradyne Shares Surge Over 20%; Check Out 20 Stocks Making Moves in Premarket Trading

9.0

10-29Benzinga

STRATA Skin Sciences Sees 25% Pre-Market Increase — Find Out the Reasons

9.0

10-03Newsfilter

Eczema Awareness Month: Clinical Research Confirms Strata Skin Sciences' XTRAC® Excimer Laser as a Revolutionary Treatment for Localized Atopic Dermatitis